Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, A Multicenter, Double-blind, Randomized, Placebo-controlled Study Verify the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets for Major Depressive Disorder

Next Previous
Trial Profile

A Phase III, A Multicenter, Double-blind, Randomized, Placebo-controlled Study Verify the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets for Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toludesvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Luye Pharma Group

Most Recent Events

  • 08 Jun 2022 According to a Luye Pharma Group media release, results from this trial were presented at the 2022 Annual Meeting of the American Psychiatric Association (APA).
  • 08 Jun 2022 Results published in the Luye Pharma Group Media Release.
  • 10 Jun 2021 According to a Luye Pharma Group media release, the marketing authorization application for the company's in-house developed Class 1 new drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration.The application for marketing authorization is based on clinical data generated from 6 clinical studies in China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top